Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 3, 2011, Pages 461-468

  Chen, Chien Hung ^a,b   Lee, Chuan Mo ^a,b   Hung, Chao Hung ^a,b   Wang, Jing Houng ^a,b   Hu, Tsung Hui ^a,b   Changchien, Chi Sin ^a,b   Lu, Sheng Nan ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

HBV genotype; Hepatitis B virus; Peginterferon; Precore mutation

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A; TELBIVUDINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SEROCONVERSION; TREATMENT RESPONSE; VIRUS REACTIVATION;

EID: 79951660421     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06429.x     Document Type: Article

References (41)

1. Sherlock S, Hepatitis B. The disease. Vaccine 1990; 8: S6-9.
2. Chen DS. From hepatitis to hepatoma: lessons from type B viral hepatitis. Science 1993; 262: 369-70.
3. Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J. Gastroenterol. Hepatol. 1997; 12: S218-S22.
4. Lee CM, Lu SN, Changchien CS etal. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 1999; 86: 1143-50.
5. Fattovich G, Rugge M, Brollo L etal. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-72.
6. Niederau C, Heintges T, Lange S etal. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N. Engl. J. Med. 1996; 334: 1422-7.
7. Fattovich G, Giustina G, Realdi G etal. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26: 1338-42.
8. Lau GKK, Piratvisuth T, Luo KX etal. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2005; 352: 2682-95.
9. Janssen HL, van Zonneveld M, Senturk H etal. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet 2005; 365: 123-29.
10. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-3.
11. Perrillo RP, Schiff ER, Davis GL etal. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J.Med. 1990; 323: 295-301.
12. Lok AS, Wu PC, Lai CL etal. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
13. Lee CM, Chen CH, Lu SN etal. Prevalence of clinical implications of hepatitis B virus genotypes in southern Taiwan. Scand J. Gastroenterol. 2003; 38: 95-101.
14. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-9.
15. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J. Hepatol. 2000; 33: 998-1002.
16. Wai CT, Chu CJ, Hussain M, Lok ASF. HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology 2002; 36: 1425-30.
17. Carman WF, Jacyna MR, Hadziyannis S etal. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
18. Brunetto MR, Giarin MM, Oliveri F etal. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl. Acad. Sci. U S A. 1991; 88: 4186-90.
19. Akahane Y, Yamanaka T, Suzuki H etal. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99: 1113-9.
20. Okamoto H, Tsuda F, Akahane Y etal. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol. 1994; 68: 8102-10.
21. Buckwold VE, Xu Z, Chen M etal. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 1996; 70: 5845-51.
22. Chen CH, Lee CM, Lu SN etal. Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J. Clin. Microbiol. 2005; 43: 6000-6.
23. Chen CH, Lee CM, Hung CH etal. Clinical significance and evolution of core promoter and precore mutations in HBeAg-positive patients with HBV genotype B and C: a longitudinal study. Liver Int. 2007; 27: 806-15.
24. Lok AS, Akarca US, Greene S. Predictive value of precore hepatitis B virus mutations in spontaneous and interferon-induced hepatitis B e antigen clearance. Hepatology 1995; 21: 19-24.
25. Marrone A, Zampino R, Luongo G, Utili R, Karayiannis P, Ruggiero G. Low HBeAg serum levels correlate with the presence of the double A1762T/G1764A core promoter mutation and a positive response to interferon in patients with chronic hepatitis B virus infection. Intervirology 2003; 46: 222-6.
26. Erhardt A, Reineke U, Blondin D etal. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-25.
27. Mizokami M, Nakano T, Orito E etal. Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns. FEBS Lett. 1999; 450: 66-71.
28. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
29. Liaw YF, Leung N, Kao JH etal. Asian-pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2008; 2: 263-83.
30. Cooksley WG, Piratvisuth T, Lee SD etal. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral. Hepat. 2003; 10: 298-305.
31. Heijtink RA, Janssen HL, Hop WC etal. Interferon-alpha therapy in chronic hepatitis B: early monitoring of hepatitis B e antigen may help to decide whether to stop or to prolong therapy. J. Viral. Hepat. 2000; 7: 382-6.
32. Hayashi PH, Beames MP, Kuhns MC, Hoofnagle JH, Di Bisceglie AM. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B. Am. J. Gastroenterol. 1996; 91: 2323-8.
33. Fried MW, Piratvisuth T, Lau GK etal. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
34. Tangkijvanich P, Komolmit P, Mahachai V, Sa-Nguanmoo P, Theamboonlers A, Poovorawan Y. Comparison between quantitative hepatitis B surface antigen, hepatitis B e-antigen and hepatitis B virus DNA levels for predicting virological response to pegylated interferon-a-2b therapy in hepatitis B e-antigen-positive chronic hepatitis B. Hepatol. Res. 2010; 40: 269-77.
35. Yen YH, Lu SN, Chen CH etal. Changes in serum hepatitis B e antigen (HBeAg) levels associated with the emergence of YMDD mutants in HBeAg non-seroconverted patients during lamivudine therapy. Liver Int. 2007; 34: 1034-55.
36. Chen CH, Lee CM, Lu SN etal. Comparison of sequence changes of precore and core promoter regions in HBeAg-positive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy. J. Hepatol. 2006; 44: 76-82.
37. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105: 1833-8.
38. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
39. Lau DT, Everhart J, Kleiner DE etal. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113: 1660-7.
40. Buster EH, Flink HJ, Cakaloglu Y etal. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135: 459-67.
41. Piratvisuth T, Lau G, Chao YC etal. Sustained response to peginterferon alfa-2a (40 kDa) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B. Hepatol. Int. 2008; 2: 102-10.